Latest On-Demand Webinars & Online Events

Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking.

To ensure the safety and efficacy of LNP-based drugs, comprehensive characterization of these sophisticated molecules–the lipids and the genetic cargo–is paramount.

Unearthing novel drug targets with robust data support and a deep understanding of biological processes remains a pivotal challenge in drug discovery. In this engaging webinar, distinguished speakers Aaron Mitchell and Rasmus Wernersson from ZS Associates will unveil a comprehensive method that significantly enhances target prediction performance through the integration of multiomics data, coupled with a data-driven, cell-type specific network biology approach.

In this webinar, you’ll hear how automated liquid handling for LC-MS/MS sample preparation contributed to the identification and quantification of over 30 metabolites that can predict adverse pregnancy outcomes, including pre-eclampsia.

In this webinar, our speaker will discuss the role of glucosyl and galactosyl ceramides as biomarkers and how their misregulation can be an identifier for various disease states including, but not limited to, Parkinson’s, Krabbe and Gaucher diseases.

This webinar highlights a platform that can identify biomarkers with clinical benefit in non-small cell lung cancer and analyze the immune microenvironment in bone marrow trephine samples.

In this webinar, our expert speaker will discuss how to optimize your untargeted approaches on Zeno SWATH DIA using a modular workflow. With this approach, each subset of the full mass range can be individually adjusted to meet project-specific and user-defined goals, enhancing the performance and adaptability of untargeted MS tools for exposomics research.

Using the example of tumor-associated macrophages (TAMs), this webinar takes a closer look at immune cells in the tumor microenvironment (TME), helping us to gain a better understanding of how specific subtypes and their reprogramming may influence therapy efficiency.

Dr. Walker will discuss how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

This popular online event will once again bring together leading scientists in the field as they highlight the latest advancements in translational proteomics and metabolomics. Presentations will cover areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.